share_log

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024

Inotiv, Inc. 将公布2024财年第二季度财务业绩,并于2024年5月15日星期三举行电话会议
GlobeNewswire ·  05/14 07:00

WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

印第安纳州西拉斐特,2024年5月14日(GLOBE NEWSWIRE)——专门从事非临床和分析药物发现与开发服务以及研究模型及相关产品和服务的领先合同研究机构Inotiv, Inc.(纳斯达克股票代码:NOTV)(“公司” 或 “Inotiv”)今天宣布,将于周三发布截至2024年3月31日的2024财年第二季度财务业绩。2024年5月15日,股市收盘后。该公司将在美国东部时间当天下午 4:30 举行电话会议,讨论结果。

Interested parties may participate in the call by dialing:

有兴趣的人士可以通过拨打以下电话参与电话会议:

  • (888) 886-7786 (Domestic)
  • (416) 764-8658 (International)
  • 38070700 (Conference ID)
  • (888) 886-7786(国内)
  • (416) 764-8658(国际)
  • 38070700(会议 ID)

The live conference call webcast will be accessible in the Investors section of the Company's web site and directly via the following link:

电话会议网络直播可在公司网站的 “投资者” 部分直接通过以下链接观看:

For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv's web site at:

对于那些无法收听直播的人,Inotiv网站的 “投资者” 部分将提供在线重播,网址为:

About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:

关于 Inotiv
Inotiv, Inc. 是一家领先的合同研究机构,致力于提供非临床和分析性药物发现和开发服务以及研究模型及相关产品和服务。该公司的产品和服务侧重于通过发现和临床前开发阶段引入新药和医疗器械,同时提高效率、改善数据并降低将新药推向市场的成本。Inotiv致力于支持发现和开发目标,帮助研究人员充分发挥其关键研发项目的潜力,同时共同努力建设一个更健康、更安全的世界。有关 Inotiv 的更多信息可以在这里找到:

This release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact included in this release, are forward-looking statements, including, but not limited to, statements about the anticipated timing of the issuance of the Company's second quarter financial results. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "outlook," "will," "should," "can have," "likely," and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from the forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, without limitation, the Company's inability to file its second quarter 2024 Form 10-Q on a timely basis; the outcome of the completion of the preparation of the Company's financial statements; results of operations or other financial matters that are different or change from what is currently anticipated; the inability to reach a resolution with the DOJ or the impact of unfavorable terms of any such resolution; the Company's ability to comply with its covenants and obligations under its credit agreement; the Company's ability to obtain waivers or amendments related to its covenants under the credit agreement; the continuance of unfavorable sales trends; the sufficiency of the Company's liquidity and cash flows to meet its obligations; the impact of this filing on the Company's common stock, its relationships with employees, customers and suppliers; and those that are described in the Company's most recent Annual Report on Form 10-K and in other documents that the Company files or furnishes with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this announcement, whether as a result of new information, future events, changes in assumptions or otherwise.

本新闻稿可能包含1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”,涉及重大风险和不确定性。除本新闻稿中包含的历史事实陈述外,所有陈述均为前瞻性陈述,包括但不限于关于公司第二季度财务业绩预计发布时间的陈述。您可以通过前瞻性陈述与历史或当前事实不完全相关的事实来识别前瞻性陈述。这些陈述可能包括诸如 “预期”、“估计”、“预期”、“项目”、“计划”、“打算”、“相信”、“可能”、“展望”、“将”、“应该”、“可能有”、“可能” 等词语,以及与讨论未来运营或财务业绩或其他事件的时间或性质相关的其他词语和术语。所有前瞻性陈述都存在重大风险、不确定性和情况变化,可能导致实际结果和结果与前瞻性陈述存在重大差异。这些前瞻性陈述不能保证未来的业绩,涉及风险、假设和不确定性,包括但不限于公司无法及时提交2024年第二季度10-Q表格;完成公司财务报表编制的结果;与当前预期不同或变化的经营业绩或其他财务事项;无法与司法部达成决议或任何此类决议不利条款的影响; 公司遵守其信贷协议下的契约和义务的能力;公司获得与信贷协议下的契约相关的豁免或修正的能力;不利的销售趋势的持续存在;公司的流动性和现金流足以履行其义务; 本文件对公司普通股及其与员工、客户和供应商关系的影响;以及公司最新的10-K表年度报告以及公司向美国证券交易委员会提交或提供的其他文件中描述的影响。如果其中一种或多种风险或不确定性成为现实,或者基本假设被证明不正确,则实际结果可能与此类前瞻性陈述所表明或预期的结果存在重大差异。因此,提醒您不要过分依赖这些前瞻性陈述,这些陈述仅代表其发表之日。除非法律要求,否则在本公告发布之日之后,无论是由于新信息、未来事件、假设变化还是其他原因,公司均不承担或明确声明公开更新任何前瞻性陈述的义务或义务。

Company Contact Investor Relations
Inotiv, Inc. LifeSci Advisors
Beth A. Taylor, Chief Financial Officer Bob Yedid
(765) 497-8381 (516) 428-8577
btaylor@inotivco.com bob@lifesciadvisors.com
公司联系人 投资者关系
Inotiv, Inc. 生命科学顾问
贝丝·泰勒,首席财务官 鲍勃·耶迪德
(765) 497-8381 (516) 428-8577
btaylor@inotivco.com bob@lifesciadvisors.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发